Supplementary Table S3 from A Phase II Study of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab for Central Nervous System Metastases in Patients with HER2-Positive Breast Cancer
Year: 2024
Type: supplementary-materials
Abstract: Supplementary Table S3. Baseline patient and disease characteristics continued from Table 1.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4403989678